Dear friends and partners of InSphero,
A remarkable year 2020 draws to an end. The pandemic came like a thief at night. It showed us how vulnerable our modern society still is – and how much more we need to learn in the field of life science.
Our team at InSphero looks back at a challenging year which we successfully navigated together. Despite the pandemic restrictions InSphero continues to grow and we moved into a larger, new office and laboratory space this summer. Our 3D Discovery Platforms in diabetes, NASH, liver steatosis and oncology generated exciting results for our pharma and biotech partners, have helped to identify new compounds or to understand the mechanism of action of existing ones. Our drug-safety programs continue to help our partners to address hazards early on and to save time to market in the clinical phase. Very exciting for us, we have started out-licensing activities for InSphero’s first own pharmaceutical assets.
Personally, I miss the opportunities to get together with you all, whether it is at scientific conferences, at business meetings or for a private dinner. I keep my fingers crossed that we will have the chance to do this in 2021.
Thank you for the many collaborations with us this year and our best wishes for a successful and healthy new year 2021!
Jan Lichtenberg, PhD
InSphero CEO and Co-founder